Passa al contenuto
Merck

Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape.

Cell metabolism (2021-11-04)
Giulia Salvadori, Federica Zanardi, Fabio Iannelli, Riccardo Lobefaro, Claudio Vernieri, Valter D Longo
ABSTRACT

Metastatic tumors remain lethal due to primary/acquired resistance to therapy or cancer stem cell (CSC)-mediated repopulation. We show that a fasting-mimicking diet (FMD) activates starvation escape pathways in triple-negative breast cancer (TNBC) cells, which can be identified and targeted by drugs. In CSCs, FMD lowers glucose-dependent protein kinase A signaling and stemness markers to reduce cell number and increase mouse survival. Accordingly, metastatic TNBC patients with lower glycemia survive longer than those with higher baseline glycemia. By contrast, in differentiated cancer cells, FMD activates PI3K-AKT, mTOR, and CDK4/6 as survival/growth pathways, which can be targeted by drugs to promote tumor regression. FMD cycles also prevent hyperglycemia and other toxicities caused by these drugs. These data indicate that FMD has wide and differential effects on normal, cancer, and CSCs, allowing the rapid identification and targeting of starvation escape pathways and providing a method potentially applicable to many malignancies.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
D-(+)-glucosio, 45% in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
Red Blood Cell Lysing Buffer Hybri-Max, liquid, sterile-filtered, suitable for hybridoma
Sigma-Aldrich
Anti-vinculina monoclonale, clone hVIN-1, ascites fluid
Roche
Insulina, recombinant (yeast)
Sigma-Aldrich
Methyl cellulose, viscosity: 4,000 cP
Sigma-Aldrich
Collagenasi, lyophilized powder, ≥125 CDU/mg solid (CDU = collagen digestion units), 0.5-5.0 FALGPA units/mg solid
Sigma-Aldrich
Hydrocortisone, ≥98% (HPLC)
Sigma-Aldrich
Ialuronidasi, Type IV-S, powder, suitable for mouse embryo cell culture, 750-3000 units/mg solid
Sigma-Aldrich
1,1-Dimethylbiguanide hydrochloride, 97%
Sigma-Aldrich
Glucose Transporter Inhibitor IV, WZB117, The Glucose Transporter Inhibitor IV, WZB117 controls the biological activity of Glucose Transporter.